PPBT · Purple Biotech Ltd. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PPBT by emailGet an email when PPBT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PPBT, unsubscribe in one click. Privacy
📣 What PPBT Says Is Next
in 2026 · “These findings support our development roadmap as we prepare for anticipated key milestones in 2026 and advance CAPTN-3 toward IND-enabling studies.” “The NKG2A/HLA-E axis is emerging as a key post-treatment resistance mechanism, as previously shown by Dr. Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai,” said Dr. Hadas Reuveni, VP Research and Development at Purple Biotech.”
Company press release, Dec 11, 2025 · SEC filing
in 2026 · “We plan to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND) and initiate a Phase 1 study for IM1240 in 2026.”
Company press release, Nov 14, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PPBT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PPBT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.